234 related articles for article (PubMed ID: 27356916)
1. Role of the IL-1 Pathway in Dopaminergic Neurodegeneration and Decreased Voluntary Movement.
Stojakovic A; Paz-Filho G; Arcos-Burgos M; Licinio J; Wong ML; Mastronardi CA
Mol Neurobiol; 2017 Aug; 54(6):4486-4495. PubMed ID: 27356916
[TBL] [Abstract][Full Text] [Related]
2. Minocycline Rescues from Zinc-Induced Nigrostriatal Dopaminergic Neurodegeneration: Biochemical and Molecular Interventions.
Kumar V; Singh BK; Chauhan AK; Singh D; Patel DK; Singh C
Mol Neurobiol; 2016 Jul; 53(5):2761-2777. PubMed ID: 25764516
[TBL] [Abstract][Full Text] [Related]
3. Prolonged Dysfunction of Astrocytes and Activation of Microglia Accelerate Degeneration of Dopaminergic Neurons in the Rat Substantia Nigra and Block Compensation of Early Motor Dysfunction Induced by 6-OHDA.
Kuter K; Olech Ł; Głowacka U
Mol Neurobiol; 2018 Apr; 55(4):3049-3066. PubMed ID: 28466266
[TBL] [Abstract][Full Text] [Related]
4. IL-17A exacerbates neuroinflammation and neurodegeneration by activating microglia in rodent models of Parkinson's disease.
Liu Z; Qiu AW; Huang Y; Yang Y; Chen JN; Gu TT; Cao BB; Qiu YH; Peng YP
Brain Behav Immun; 2019 Oct; 81():630-645. PubMed ID: 31351185
[TBL] [Abstract][Full Text] [Related]
5. Protein kinase Cδ upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease.
Gordon R; Singh N; Lawana V; Ghosh A; Harischandra DS; Jin H; Hogan C; Sarkar S; Rokad D; Panicker N; Anantharam V; Kanthasamy AG; Kanthasamy A
Neurobiol Dis; 2016 Sep; 93():96-114. PubMed ID: 27151770
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-18 null mice show diminished microglial activation and reduced dopaminergic neuron loss following acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment.
Sugama S; Wirz SA; Barr AM; Conti B; Bartfai T; Shibasaki T
Neuroscience; 2004; 128(2):451-8. PubMed ID: 15350655
[TBL] [Abstract][Full Text] [Related]
7. GPER activation is effective in protecting against inflammation-induced nigral dopaminergic loss and motor function impairment.
Mendes-Oliveira J; Lopes Campos F; Videira RA; Baltazar G
Brain Behav Immun; 2017 Aug; 64():296-307. PubMed ID: 28450223
[TBL] [Abstract][Full Text] [Related]
8. Running exercise protects the substantia nigra dopaminergic neurons against inflammation-induced degeneration via the activation of BDNF signaling pathway.
Wu SY; Wang TF; Yu L; Jen CJ; Chuang JI; Wu FS; Wu CW; Kuo YM
Brain Behav Immun; 2011 Jan; 25(1):135-46. PubMed ID: 20851176
[TBL] [Abstract][Full Text] [Related]
9. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M
J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135
[TBL] [Abstract][Full Text] [Related]
10. Switching the microglial harmful phenotype promotes lifelong restoration of subtantia nigra dopaminergic neurons from inflammatory neurodegeneration in aged mice.
L'episcopo F; Tirolo C; Testa N; Caniglia S; Morale MC; Impagnatiello F; Marchetti B
Rejuvenation Res; 2011 Aug; 14(4):411-24. PubMed ID: 21793734
[TBL] [Abstract][Full Text] [Related]
11. Ibuprofen abates cypermethrin-induced expression of pro-inflammatory mediators and mitogen-activated protein kinases and averts the nigrostriatal dopaminergic neurodegeneration.
Singh A; Tripathi P; Prakash O; Singh MP
Mol Neurobiol; 2016 Dec; 53(10):6849-6858. PubMed ID: 26660326
[TBL] [Abstract][Full Text] [Related]
12. Lack of interleukin-13 receptor α1 delays the loss of dopaminergic neurons during chronic stress.
Mori S; Sugama S; Nguyen W; Michel T; Sanna MG; Sanchez-Alavez M; Cintron-Colon R; Moroncini G; Kakinuma Y; Maher P; Conti B
J Neuroinflammation; 2017 Apr; 14(1):88. PubMed ID: 28427412
[TBL] [Abstract][Full Text] [Related]
13. Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra.
Ferrari CC; Pott Godoy MC; Tarelli R; Chertoff M; Depino AM; Pitossi FJ
Neurobiol Dis; 2006 Oct; 24(1):183-93. PubMed ID: 16901708
[TBL] [Abstract][Full Text] [Related]
14. Melatonin inhibits manganese-induced motor dysfunction and neuronal loss in mice: involvement of oxidative stress and dopaminergic neurodegeneration.
Deng Y; Jiao C; Mi C; Xu B; Li Y; Wang F; Liu W; Xu Z
Mol Neurobiol; 2015 Feb; 51(1):68-88. PubMed ID: 24969583
[TBL] [Abstract][Full Text] [Related]
15. Minocycline inhibition of microglial rescues nigrostriatal dopaminergic neurodegeneration caused by mutant alpha-synuclein overexpression.
Wang Y; Wang Q; Yu R; Zhang Q; Zhang Z; Li H; Ren C; Yang R; Niu H
Aging (Albany NY); 2020 Jul; 12(14):14232-14243. PubMed ID: 32706757
[TBL] [Abstract][Full Text] [Related]
16. Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease.
González H; Contreras F; Prado C; Elgueta D; Franz D; Bernales S; Pacheco R
J Immunol; 2013 May; 190(10):5048-56. PubMed ID: 23589621
[TBL] [Abstract][Full Text] [Related]
17. Anesthetic Effects on the Progression of Parkinson Disease in the Rat DJ-1 Model.
Xu DA; DeYoung TP; Kondoleon NP; Eckenhoff RG; Eckenhoff MF
Anesth Analg; 2021 Nov; 133(5):1140-1151. PubMed ID: 34673725
[TBL] [Abstract][Full Text] [Related]
18. Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration.
Choi DY; Lee MK; Hong JT
Neurobiol Dis; 2013 Jan; 49():159-68. PubMed ID: 22922220
[TBL] [Abstract][Full Text] [Related]
19. Genetic suppression of collapsin response mediator protein 2 phosphorylation improves outcome in methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's model mice.
Togashi K; Hasegawa M; Nagai J; Tonouchi A; Masukawa D; Hensley K; Goshima Y; Ohshima T
Genes Cells; 2019 Jan; 24(1):31-40. PubMed ID: 30375127
[TBL] [Abstract][Full Text] [Related]
20. Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.
Korecka JA; Moloney EB; Eggers R; Hobo B; Scheffer S; Ras-Verloop N; Pasterkamp RJ; Swaab DF; Smit AB; van Kesteren RE; Bossers K; Verhaagen J
J Neurosci; 2017 Sep; 37(39):9361-9379. PubMed ID: 28842419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
